CLARITHROMYCIN SANDOZ clarithromycin 500 mg film-coated tablets blister pack Австралия - английский - Department of Health (Therapeutic Goods Administration)

clarithromycin sandoz clarithromycin 500 mg film-coated tablets blister pack

sandoz pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; macrogol 4000; hypromellose; titanium dioxide; microcrystalline cellulose; powdered cellulose - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis.acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae;combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. clarithromycin sandoz clarithromycin is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro organisms in the conditions listed below:acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; skin and skin structure infections (eg impetigo); disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. acute otitis media.note:1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of clarithromycin in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

L.C.E. SANDOZ 200/50/200 levodopa 200 mg, carbidopa (as carbidopa monohydrate) 50 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 200/50/200 levodopa 200 mg, carbidopa (as carbidopa monohydrate) 50 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: iron oxide yellow; croscarmellose sodium; povidone; magnesium stearate; polysorbate 80; glycerol; sucrose; iron oxide red; hypromellose; mannitol; titanium dioxide; maize starch - l.c.e. sandoz 150/37.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 125/31.25/200 levodopa 125 mg, carbidopa  (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 125/31.25/200 levodopa 125 mg, carbidopa (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 100/25/200 levodopa 100 mg, carbidopa  (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 75/18.75/200 levodopa 75 mg, carbidopa  (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle Австралия - английский - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

IRBESARTAN/HCT SANDOZ  300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack Австралия - английский - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ  150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack Австралия - английский - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ  300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack Австралия - английский - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.